Sphingotec, Nexus Dx Merge Tech Platforms for POC Testing in ER, ICU

May 22, 2018

|

NEW YORK (360Dx) – Hennigsdorf, Germany-based Sphingotec said today that it has combined technology platforms with San Diego, California-based Nexus Dx to improve decision-making at the point of care in emergency departments and intensive care units.

Financial and other terms of the deal were not disclosed.

Holding company Polaris MediNet — jointly owned by Sphingotec and Nam Shin, CEO of Nexus Dx — merged the technology platforms.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Performance of SARS-CoV-2 Assay in Extraction-free Method Compared to that of Conventional RNA Extraction using Automated Instrument

The Importance of Sample Pooling in COVID-19 Testing

The Importance of Limit of Detection in COVID-19 Tests

How To Start COVID-19 Testing In Your Lab

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

May

10

Featured Webinar

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May

18

Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.

Menu

Sphingotec, Nexus Dx Merge Tech Platforms for POC Testing in ER, ICU

To read the full story....

Breaking News

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

Featured White Papers

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

FDA Grants EUAs for SARS-CoV-2 Tests From Clinical Enterprise, Qorvo Biotechnologies

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

Sponsorships